AVALIAÇÃO DA EFETIVIDADE DO PROGRAMA DE TRATAMENTO DA HEPATITE C CRÔNICA EM USUÁRIOS DA FARMÁCIA ESTADUAL DE MEDICAMENTOS EXCEPCIONAIS DO MARANHÃO (FEME).

• Ano de defesa: 2011
• Autor(a) principal: TEIXEIRA, Fábio Gomes
• Orientador(a): FERREIRA, Adalgisa de Souza Paiva
• Banca de defesa: FERREIRA, Adalgisa de Souza Paiva
• Tipo de documento: Dissertação
• Tipo de acesso: Acesso aberto
• Idioma: por
• Instituição de defesa: Universidade Federal do Maranhão
• Programa de Pós-Graduação: PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS DA SAÚDE/CCBS
• Departamento: DEPARTAMENTO DE MEDICINA I/CCBS
• País: Brasil
• Palavras-chave em Português: Hepatite C Crônica; Tratamento; Resposta
• Palavras-chave em Inglês: Chronic Hepatitis C; Treatment; Response
• Área do conhecimento CNPq: Gastroenterologia
• Link de acesso: https://tedebc.ufma.br/jspui/handle/tede/1989

Cohort study using retrospective data to evaluate the effectiveness of the treatment program for chronic hepatitis C in users of Farmácia Estadual de Medicamentos Excepcionais do Maranhão (FEME) to determine the rate of sustained virologic response (SVR) and correlate it with demographic, clinical, laboratory, histological and virological features of patients and to identify the rates of discontinuation of treatment. We analyzed data from 256 patients treated for chronic hepatitis C in FEME for the period January 2005 to July 2009, being an SVR by intention to treat 57%. Males predominated (66%). The mean age was 52.5 years, with a predominance of non-white individuals in relation to whites. Genotype 1 was the most common (77%) and 150 (58.6%) patients had viral load above 400,000 UI/ml. With respect to the treatment regimen, pegylated interferon associated with ribavirin was used by 80.5% of patients, the rate of discontinuation of treatment of 13,3%. They were identified as factors independently associated with SVR: white, non-cirrhotic, have not a genotype 1 and viral load below 400,000 IU / ml. These findings demonstrate the effectiveness of treatment provided by FEME, which makes it possible to cure most patients, preventing progression to end-stage liver disease and its disastrous consequences. The factors associated with SVR have seen in other studies, leads us to believe that the results are reliable and that the program is fulfilling the role it has set itself.